our vision
To be the North American leader in neurology through the quality of our people, the quality of our products, and our focus on the patient.
our values
  • Personal commitment
  • High integrity
  • Strong teamwork
  • Achievement oriented
  • Create opportunity
  • Sense of satisfaction
careers
At Teva Neuroscience, we strive to be the place where our culture, values and opportunities contribute to attract the highest quality individuals. We are interested in considering candidates who are a fit with the Company's culture and values for all positions.

Teva Neuroscience: "The place where the best people choose to work"
view positions

You need Adobe Flash Player to properly view this page. Please install Flash Player here

AZILECT.com

We are pleased to announce that AZILECT® was approved by the Food and Drug Administration and is now available in pharmacies by prescription only. Please visit the AZILECT® Web site to learn more.

AZILECT® is indicated for the treatment of the signs and symptoms of Parkinson’s disease (PD) both as initial therapy alone and to be added to levodopa later in the disease.

The effectiveness of AZILECT® was shown in patients with early PD who were receiving AZILECT® as initial therapy alone and who were not receiving any other PD therapy. The effectiveness of AZILECT® as adjunct therapy was shown in patients with PD who were treated with levodopa.

Managing PD can be difficult, but with the right information you can help take control of the disease.

Check out AZILECT.com for:

  • Information on AZILECT®.
  • Find out if AZILECT® is right for you.
  • Tools to help you track your symptoms.
  • Special information for caregivers.
        086463117/080425

COPAXONE® (glatiramer acetate injection) is a registered trademark of Teva Pharmaceutical Industries Ltd.
AZILECT® (rasagiline tablets) is a registered trademark of Teva Pharmaceutical Industries Ltd.
Shared Solutions® is a registered trademark of Teva Neuroscience, Inc.
This site is intended for U.S. audiences only
© 2008 Teva Neuroscience, Inc.